TITLE

Effect of soy isoflavones on breast cancer recurrence and death for patients receiving adjuvant endocrine therapy

AUTHOR(S)
Xinmei Kang; Qingyuan Zhang; Shuhuai Wang; Xu Huang; Shi Jin
PUB. DATE
November 2010
SOURCE
CMAJ: Canadian Medical Association Journal;11/23/2010, Vol. 182 Issue 17, p1857
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: The intake of soy isoflavones among women with breast cancer has become a public health concern, because these compounds have weak estrogenic effects. There is little clinical evidence about their safety for patients with breast cancer who are receiving adjuvant endocrine therapy. Methods: For patients who underwent surgery for breast cancer between August 2002 and July 2003 and who were receiving adjuvant endocrine therapy, we examined associations between dietary intake of soy isoflavones and recurrence of breast cancer and death. We measured dietary intake of soy isoflavones at baseline using a validated food frequency questionnaire. We estimated hazard ratios (HRs) and 95% confidence intervals (CIs) by means of multivariable Cox proportional hazards regression models. We further stratified the analyses by hormonal receptor status and endocrine therapy. Results: The median follow-up period for the 524 patients in this study was 5.1 years. Among premenopausal patients, the overall death rate (30.6%) was not related to intake of soy isoflavones (HR = 1.05, 95% CI 0.78-1.71 for the highest quartile [> 42.3 mg/day] v. the lowest quartile [< 15.2 mg/day], p for trend = 0.87). Relative to postmenopausal patients in the lowest quartile of soy isoflavone intake, the risk of recurrence for postmenopausal patients in the highest quartile was significantly lower (HR = 0.67, 95% CI 0.54-0.85, p for trend = 0.02). Inverse associations were observed in patients with estrogen and progesterone receptor positive disease and those receiving anastrozole therapy. Interpretation: High dietary intake of soy isoflavones was associated with lower risk of recurrence among postmenopausal patients with breast cancer positive for estrogen and progesterone receptor and those who were receiving anastrozole as endocrine therapy.
ACCESSION #
55703747

 

Related Articles

  • Mortality Rates Among Early-Stage Hormone Receptor–Positive Breast Cancer Patients: A Population-Based Cohort Study in Denmark. Christiansen, Peer; Bjerre, Karsten; Ejlertsen, Bent; Jensen, Maj-Britt; Rasmussen, Birgitte B.; Lænkholm, Anne-Vibeke; Kroman, Niels; Ewertz, Marianne; Offersen, Birgitte; Toftdahl, Dorte B.; Møller, Susanne; Mouridsen, Henning T. // JNCI: Journal of the National Cancer Institute;Sep2011, Vol. 103 Issue 18, p1363 

    Background Indications for adjuvant endocrine treatment of breast cancer have gradually increased over the past several years. We aimed to define subgroups of patients who may or may not benefit from adjuvant endocrine therapy. Methods A population-based cohort of systemically untreated breast...

  • RIVER of HOPE. Kanigel, Rachele // Natural Health;Oct2007, Vol. 37 Issue 9, p90 

    The article reports on the decline in the rates of breast cancer in the U.S. It reports that breast cancer rates are now at their lowest level since 1987. According to a study published in the "New England Journal of Medicine," in 2003 and 2004, 30,000 fewer women developed breast cancer than...

  • The Expanding Use of Third-Generation Aromatase Inhibitors: What the General Internist Needs to Know. Hong, Susan; Didwania, Aarati; Olopade, Olufunmilayo; Ganschow, Pamela // JGIM: Journal of General Internal Medicine;Nov2009 Supplement 2, Vol. 24, p383 

    Breast cancer patients represent the largest group of adult cancer survivors in the US. Most breast cancers in women 50 years of age and older are hormone receptor positive. Third generation aromatase inhibitors (AIs) are the newest class of drugs used in treating hormone responsive breast...

  • Undertreated Breast Cancer in the Elderly. Malik, Manmeet Kaur; Tartter, Paul Ian; Belfer, Rachel // Journal of Cancer Epidemiology;2013, p1 

    The effect of undertreatment with adjuvant hormonal therapy, chemotherapy, or radiation was studied in elderly women with breast cancer. A prospectively maintained database was used to identify women undergoing potentially curative surgery between 1978 and 2012. The presentation, pathologic...

  • Margin Status Influence on the Outcome of Patients Treated with Breast Conserving Surgery. M. E., Akbari; M., Akbari; H., Zirakzadeh; N., Nafisi; A., Heidari; F., Hosseinizadegan Shirazi // Iranian Journal of Cancer Prevention;Sep2011, Vol. 4 Issue 4, p177 

    Background: Breast conserving surgery (BCS) followed by local radiotherapy is the standard treatment for early stage of breast cancer. Margin status may have an important impact on local recurrence and overall survival of patients treated with BCS, but this has not been defined adequately. In...

  • Immune checkpoints: Cytotoxic T-lymphocyte antigen 4 and programmed cell death protein 1 in breast cancer surgery. KOLACINSKA, AGNIESZKA; CEBULA-OBRZUT, BARBARA; PAKULA, LUKASZ; CHALUBINSKA-FENDLER, JUSTYNA; MORAWIEC-SZTANDERA, ALINA; PAWLOWSKA, ZOFIA; ZAWLIK, IZABELA; MORAWIEC, ZBIGNIEW; JESIONEK-KUPNICKA, DOROTA; SMOLEWSKI, PIOTR // Oncology Letters;Aug2015, Vol. 10 Issue 2, p1079 

    Immune checkpoints refer to a plethora of inhibitory pathways built into the immune system, and recent studies have emphasized the role of these checkpoints in carcinogenesis. The aim of the present study was to evaluate two major immune checkpoints, the cytotoxic T-lymphocyte antigen 4 (CTLA-4)...

  • Pathological characteristics of very young (≤30 years) breast cancer patients: a single-institution experience from Turkey. Aksoy, S.; Bulut, N.; Dizdar, O.; Tosur, M.; Meral, A.; Altundag, K. // Annals of Oncology;Apr2009, Vol. 20 Issue 4, p790 

    This article discusses a study which compared pathological risk factors of women with breast cancer aged 30 years and below with those aged 31-50 years. The study was conducted between 2004-07. Particular focus is given to the percentages of tumors classified as estrogen receptor negative and...

  • ER, PR, AND HER-2/NEU PROFILE ON YOUNG BREAST CARCINOMA PATIENTS. Vidiyanti, Caesarisma; Fauziah, Dyah; Agung Suprabawati, Desak Gede // Folia Medica Indonesiana;2014, Vol. 50 Issue 1, p15 

    Breast carcinoma is one of the most common malignancy in women with increasing incidence rate every year. Evidence strongly suggested the cancer tends to occur at younger age. The aim of this study is to observe the characteristic of estrogen receptor (ER), progesterone receptor (PR), and...

  • Correlation of high F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer. Groheux, David; Giacchetti, Sylvie; Moretti, Jean-Luc; Porcher, Raphael; Espié, Marc; Lehmann-Che, Jacqueline; Roquancourt, Anne; Hamy, Anne-Sophie; Cuvier, Caroline; Vercellino, Laetitia; Hindié, Elif // European Journal of Nuclear Medicine & Molecular Imaging;Mar2011, Vol. 38 Issue 3, p426 

    Purpose: The aim of this study was to determine the impact of the main clinicopathological and biological prognostic factors of breast cancer on F-fluorodeoxyglucose (FDG) uptake. Only women with tumours larger than 20 mm (T2-T4) were included in order to minimize bias of partial volume effect....

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics